Skip to main content

Table 1 Sample characteristics

From: Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

Treatment preparation IFNβ-1a i.m. IFNβ-1a s.c. IFNβ-1b s.c.
Cohort KI Sweden TUM Germany KI Sweden TUM Germany KI Sweden TUM Germany
N (%) 345 (24.7) 251 (18.4) 590 (42.3) 558 (40.9) 459 (32.9) 554 (40.6)
Mean age (SD) 46.7 (9.9) 40.1 (9.6) 44.1 (9.9) 38.9 (9.6) 45.4 (10.4) 41.4 (10.4)
Female sex (%) 216 (62.6) 191 (76.1) 440 (74.6) 406 (72.8) 334 (72.8) 390 (70.4)
Median treatment duration in months (MAD) 21.0 (8.1) 40.0 (20.4) 30.0 (15.0) 55.2 (23.1) 24.9 (12.9) 46.9 (23.4)
Progressive MS (%) 60 (17.4) 34 (13.5) 120 (20.3) 90 (16.1) 130 (28.3) 128 (23.1)
nADA positive (%) 45 (13.0) 41 (16.3) 204 (34.6) 188 (33.7) 245 (53.4) 255 (46.0)
Median nADA titer (MAD) nADA-positive samples 320 (280) 320 (280) 640 (600) 1280 (1240) 320 (280) 320 (280)
Median bADA level (MAD) all samples 13.9 (6.5) 9.6 (5.7) 23.2 (13.9) 16.3 (10.5) 35.8 (19.9) 29.4 (20.0)
Median bADA level (MAD) nADA-positive samples 63.8 (42.6) 25.8 (22.3) 109.0 (84.8) 115.0 (104.0) 69.0 (37.0) 73.8 (50.7)
  1. N (%) refers to the entire cohort, the other percentages to the respective column. The nADA and bADA measurements shown here were obtained within the present study. Non-parametric summary statistics are provided for variables that were not normally distributed. Progressive MS = patients with a primary or secondary progressive disease course, as opposed to clinically isolated syndrome and relapsing-remitting MS. The dataset contained 1.6% primary progressive, 0.6% progressive-relapsing, and 18.2% secondary progressive MS patients. The frequency of nADA did not differ between progressive (35.2%) and other (35.5%) MS patients. Patients were diagnosed using the current McDonald criteria at the time of diagnosis. KI Karolinska Institutet, Sweden; TUM Technical University of Munich, Germany; SD standard deviation; MAD median absolute deviation